<DOC>
	<DOCNO>NCT02328209</DOCNO>
	<brief_summary>Recently study show intravitreal injection ranibizumab effective age relate macular degeneration . However problem injection regimen maintenance phase . We plan perform new simplify treat extend regimen use ranibizumab .</brief_summary>
	<brief_title>Evaluation Simplified Treat And Extend Regimen Using Ranibizumab Exudative Age Related Macular Degeneration</brief_title>
	<detailed_description>The purpose present study evaluate simplify treat extend regimen use ranibizumab eye wet age relate macular degeneration best-corrected visual acuity , central retinal thickness , disappearance rate morphological change treatment continuous rate .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. ability provide write informed consent study 2. age &gt; =50years old 3. intravitreal injection ranibizumab first therapy neovascular agerelated macular degeneration ( typical agerelated macular degeneration PCV ) 4. best correct visual acuity &gt; =0.05 1. past intravitreal antivascular endothelial growth factor therapy study eye 2. past intravitreal subtenon injection steroid therapy study eye 3. past vitrectomy therapy study eye 4. infection suspicion infection eye periocular region 5. severe intraocular inflammation eye 6. past allergic reaction ranibizumab 7. past allergic reaction fluorescein , indocyanine green iodine 8. pregnancy ( positive pregnancy test ) lactate woman 9. condition investigator believe would pose significant hazard subject investigational therapy initiate .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>